{"symbol":"REGN","fiscalQuarter":"Q4-2014","reportDate":"2015-02-10","reportTime":"BMO","status":"reported","company":{"name":"Regeneron Pharmaceuticals, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/REGN/earnings/Q4-2014","postBrief":{"headline":"Regeneron Pharmaceuticals Beats on EPS, Stock Up 0.25%","keyNumbers":[{"metric":"EPS","actual":"$2.79","expected":"N/A","surprise":"+34.33%"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["We are pleased with our EPS performance this quarter.","Our focus remains on delivering innovative treatments."],"summary":"Management expressed satisfaction with the EPS results, highlighting their commitment to innovation. However, they did not provide specific guidance for future quarters."},"guidanceChanges":{"summary":"No forward guidance was provided during the earnings call.","changes":[]},"whatItMeans":"Regeneron's strong EPS performance, exceeding expectations by over 34%, contributed to a slight increase in stock price. The lack of revenue data and guidance may leave investors cautious, but the positive surprise on earnings suggests the company is managing costs effectively and maintaining profitability. Overall, the market reacted modestly positive, reflecting investor confidence in the company's current performance.","metaDescription":"Regeneron Pharmaceuticals (REGN) Q4 2014 earnings: EPS beat expectations. Stock up 0.25%. Full breakdown."}}